Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd.

Biotechnology • Healthcare • Jerusalem, Israel • SCNI (NCM)

Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

This Is Why Scinai Immunotherapeutics Ltd.'s (NASDAQ:SCNI) CEO Compensation Looks Appropriate - simplywall.st
simplywall.st • Dec 15
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l. - PR Newswire
PR Newswire • Jun 5
Scinai Immunotherapeutics Shareholders Approve Share Increase, Equity Grants and Auditor at December 22 Meeting - TipRanks
TipRanks • Dec 23
Scinai Stock Leap: Why Now? - StocksToTrade
StocksToTrade • Jun 5
Scinai Immunotherapeutics Reports Nine-Month 2025 Results and Strategic Developments - TipRanks
TipRanks • Dec 2

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Scinai Immunotherapeutics Ltd. had layoffs?
No layoff events have been recorded for Scinai Immunotherapeutics Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Scinai Immunotherapeutics Ltd. have?
Scinai Immunotherapeutics Ltd. has approximately 31 employees.
What industry is Scinai Immunotherapeutics Ltd. in?
Scinai Immunotherapeutics Ltd. operates in the Biotechnology industry, within the Healthcare sector.
Is Scinai Immunotherapeutics Ltd. a publicly traded company?
Yes, Scinai Immunotherapeutics Ltd. is publicly traded under the ticker symbol SCNI on the NCM. The company has a market capitalization of approximately $0.00 billion.
Where is Scinai Immunotherapeutics Ltd. headquartered?
Scinai Immunotherapeutics Ltd. is headquartered in Jerusalem, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.